Ruffer LLP Makes New Investment in Jazz Pharmaceuticals PLC $JAZZ

Ruffer LLP acquired a new position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the fourth quarter, according to the company in its most recent filing with the SEC. The fund acquired 14,242 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,425,000.

A number of other institutional investors have also recently added to or reduced their stakes in JAZZ. Royal Bank of Canada lifted its holdings in Jazz Pharmaceuticals by 96.5% in the 1st quarter. Royal Bank of Canada now owns 67,614 shares of the specialty pharmaceutical company’s stock worth $8,394,000 after buying an additional 33,210 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Jazz Pharmaceuticals by 147.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company’s stock valued at $43,652,000 after purchasing an additional 209,667 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Jazz Pharmaceuticals by 4.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 197,174 shares of the specialty pharmaceutical company’s stock valued at $24,479,000 after purchasing an additional 7,954 shares in the last quarter. Focus Partners Wealth raised its stake in shares of Jazz Pharmaceuticals by 3.4% in the 1st quarter. Focus Partners Wealth now owns 4,623 shares of the specialty pharmaceutical company’s stock valued at $574,000 after purchasing an additional 154 shares in the last quarter. Finally, Geneos Wealth Management Inc. raised its stake in shares of Jazz Pharmaceuticals by 57.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 137 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Truist Financial upgraded shares of Jazz Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, March 25th. Raymond James Financial assumed coverage on shares of Jazz Pharmaceuticals in a research note on Friday, April 10th. They issued an “outperform” rating and a $227.00 target price on the stock. Weiss Ratings restated a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research note on Friday, March 27th. Piper Sandler upped their target price on shares of Jazz Pharmaceuticals from $219.00 to $232.00 and gave the company an “overweight” rating in a research note on Thursday, March 19th. Finally, TD Cowen restated a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Thursday, January 29th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Jazz Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $216.87.

Insider Activity

In related news, EVP Neena M. Patil sold 55,600 shares of the stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $191.56, for a total transaction of $10,650,736.00. Following the sale, the executive vice president owned 56,862 shares in the company, valued at $10,892,484.72. This represents a 49.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bruce C. Cozadd sold 6,000 shares of the stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $190.50, for a total transaction of $1,143,000.00. Following the sale, the director owned 384,682 shares in the company, valued at approximately $73,281,921. This trade represents a 1.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 74,015 shares of company stock valued at $14,180,486 over the last quarter. Corporate insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Price Performance

JAZZ opened at $202.40 on Thursday. The firm has a market cap of $12.46 billion, a price-to-earnings ratio of -33.90, a price-to-earnings-growth ratio of 0.35 and a beta of 0.23. Jazz Pharmaceuticals PLC has a fifty-two week low of $97.50 and a fifty-two week high of $207.48. The company’s 50-day moving average price is $185.67 and its 200 day moving average price is $168.17. The company has a quick ratio of 1.67, a current ratio of 1.86 and a debt-to-equity ratio of 1.00.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Wednesday, February 25th. The specialty pharmaceutical company reported $6.64 earnings per share for the quarter, topping the consensus estimate of $6.49 by $0.15. The firm had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.17 billion. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 6.87%. Jazz Pharmaceuticals’s quarterly revenue was up 8.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $6.51 earnings per share. As a group, sell-side analysts expect that Jazz Pharmaceuticals PLC will post 20.65 earnings per share for the current year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.